Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Unit price / market price
-
$0.8108
-
Total 13F principal
-
$302,112,167
-
Principal change
-
-$10,871,000
-
Total reported value
-
$244,546,345
-
Number of holders
-
21
-
Value change
-
-$10,623,621
-
Number of buys
-
9
-
Number of sells
-
7
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q2 2023
As of 30 Jun 2023 TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 had 21 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $302,112,167 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included WOLVERINE ASSET MANAGEMENT LLC, CAPSTONE INVESTMENT ADVISORS, LLC, D. E. Shaw & Co., Inc., BRAIDWELL LP, LAZARD ASSET MANAGEMENT LLC, UBS OCONNOR LLC, AVIVA PLC, CITIGROUP INC, Linden Advisors LP, and READYSTATE ASSET MANAGEMENT LP.
This table shows 21 bond principal holders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.